Biznes · 26.02.20101 min czytania
Prospective Grant of Exclusive License: Treatment of Glaucoma by Administration of Adenosine A3 Antagonists
Automatyczne tłumaczenie lokalne · Oryginalny język źródła
Streszczenie
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Provisional Patent Application 60/010,737, entitled "Dihydropyridine, pyridine-, benzopyran one-, and triazoloquinazoline derivatives, their preparation and use as adenosine receptor antagonists," filed January 29, 1996 [HHS Ref. No. E-225-1995/0-US-1], U.S. Provisional Patent Application 60/021,191, entitled "Dihydropyridine, pyridine-, benzopyran one-, and triazoloquinazoline derivatives, their preparation and use as adenosine receptor antagonists," filed July 3, 1996 [HHS Ref. No. E-225-1995/1-US-1], PCT Application PCT/US97/01252, entitled "Dihydropyridine, pyridine-, benzopyran one-, and triazoloquinazoline derivatives, their preparation and use as adenosine receptor antagonists," filed January 29, 1997 [HHS Ref. No. E-225-1995/2-PCT- 1], U.S. Patent 6,066,642, entitled "Dihydropyridine, pyridine-, benzopyran one-, and triazoloquinazoline derivatives, their preparation and use as adenosine receptor antagonists,"